Accessibility to oral antiviral therapy for patients with chronic hepatitis c in the united states

Journal of Clinical and Translational Hepatology

Volumn 4, Issue 2, 2016, Pages 76-82

  Saab, Sammy ^a,b   Jimenez, Melissa ^b   Fong, Tiffany ^b   Wu, Crystal ^b   Bau, Sherona ^b   Jamal, Zoha ^b   Grotts, Jonathan ^b   Elashoff, David ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral therapy; Healthcare access; Hepatitis C

Indexed keywords

EID: 85005788388     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2016.00011     Document Type: Article

References (32)

1. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011;31:1090–1101. doi: 10. 1111/j.1478-3231.2011.02494.x.
2. Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014;39:518–531. doi: 10.1111/apt.12625.
3. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hep-atology. 2001;34:809–816. doi: 10.1053/jhep.2001.27831.
4. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140:1182–1188.e1. doi: 10.1053/j.gastro. 2010.12.032.
5. Kim WR, Stock PG, Smith JM, Heimbach JK, Skeans MA, Edwards EB, et al. OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant 2013;1:73–102. doi: 10.1111/ajt.12021.
6. Stefanova-Petrova DV, Tzvetanska AH, Naumova EJ, Mihailova AP, Hadjiev EA, Dikova RP, et al. Chronic hepatitis C virus infection: prevalence of extra-hepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol. 2007;13:6518–6528. doi: 10.3748/wjg.13. 6518.
7. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a com-munity-based long-term prospective study. J Infect Dis. 2012;206:469–477. doi: 10.1093/infdis/jis385.
8. Koh C, Heller T, Haynes-Williams V, Hara K, Zhao X, Feld JJ, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther 2013;37:887–894. doi: 10.1111/apt. 12273.
9. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–2593. doi: 10.1001/jama.2012.144878.
10. Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol. 2014;109:1576–1584. doi: 10.1038/ajg.2014.243.
11. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastro-enterology. 2003;124:1711–1719. doi: 10.1016/S0016-5085(03)00394-9.
12. Slim J, Afridi MS. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV. Infect Dis Clin North Am. 2012;26:917–929. doi: 10.1016/j.idc.2012.08.006.
13. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385: 1124–1135. doi: 10.1016/S0140-6736(14)62401-6.
14. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348: g3308. doi: 10.1136/bmj.g3308.
15. Boccaccio V, Bruno S. Optimal management of patients with chronic hepatitis C and comorbidities. Liver Int. 2015;35:35–43. doi: 10.1111/liv.12712.
16. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397–406. doi: 10.7326/M14-1336.
17. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162:407–419. doi: 10.7326/M14-1152.
18. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology. 2014;60:37–45. doi: 10.1002/hep.27151.
19. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41:544–563. doi: 10.1111/apt.13081.
20. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, et al. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med. 2016;176:65–73. doi: 10.1001/jamainternmed.2015.6011.
21. http://factfinder.census.gov/faces/nav/jsf/pages/community_facts.xhtml, accessed August 2015.
22. www.HCVguidelines.org. Accessed November, 2015.
23. Do A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C, et al. Drug Author-ization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. PLoS One. 2015;10:e0135645. doi: 10.1371/journal.pone.0135645.
24. Lo Re V, Gowda C, Urick PN, Halladay J, Binkley A, Carbonari DM, et al. Incidence and determinants of denial of DAA therapy by type of insurance during the first 6 months of the modern HCV treatment era. AASLD 2015. 13–17 Nov, 2015. San Francisco.
25. http://www.dhcs.ca.gov/Pages/HepatitisC.aspx. Accessed. December 2015.
26. Yuan Y, Iloeje UH, Hay J, Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm. 2008;14:21–33. doi: 10.18553/jmcp.2008. 14.1.21.
27. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010;13: 922–933. doi: 10.1111/j.1524-4733.2010.00782.x.
28. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271–278. doi: 10.7326/0003-4819-156-4-201202210-00004.
29. Chen DS, Locarnini S, Wallace J. From the big three to the big four. Lancet Infect Dis. 2015;15:626–627. doi: 10.1016/S1473-3099(15)00026-2.
30. Stepanova M, Younossi ZM. Interferon-free regimens for chronic hepatitis C: barriers due to treatment candidacy and insurance coverage. Dig Dis Sci. 2015;60:3248–3251. doi: 10.1007/s10620-015-3709-6.
31. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013;57:1325–1332. doi: 10.1002/hep. 26246.
32. Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat. 2013;20:745–760. doi: 10.1111/jvh.12173.